Launching a new clinical study is an exciting stage of product
development. There is tremendous hope that a new drug will
cure illness or bring relief to patients. Inspired, the team jumps
in with a sense of urgency – but as documents and tasks pile
up, bottlenecks emerge that delay getting actual research
started and threaten the team’s ability to meet key study
milestones for product registration. Rik van Mol, at Veeva
Systems, submits a white paper on accelerating the pace of
study start-up.